16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

In-Person & Virtual

Korean Society of Medical Oncology

• Full Name:

Ji Won Park

- Current Position & Affiliation: Professor, Department of Surgery, Seoul National University Hospital, Seoul, South Korea
- Country:

Republic of Korea

• Educational Background:

2023

- 2009-2019 Ph.D. in Medicine Chungbuk National University, Cheongju, Korea
- 2006-2008 M.S. in Medicine Chungbuk National University, Cheongju, Korea
- 1995-2001 B.S. in Medicine
 Seoul National University College of Medicine, Seoul, Korea

• Professional Experience:

- 2022-present Professor Department of Surgery, Seoul National University Hospital, Seoul, Korea
- 2019-2020 Visiting Scholar
 Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- 2017-2022 Associate Professor
 Department of Surgery, Seoul National University Hospital, Seoul, Korea
- 2013-2017 Assistant Professor
 Department of Surgery, Seoul National University Hospital, Seoul, Korea
- 2008-2013 Attending Surgeon Center for Colorectal Cancer, National Cancer Center, Goyang, Korea
- 2006-2008 Fellowship Center for Colorectal Cancer, National Cancer Center, Goyang, Korea

• Professional Organizations:

- Member, Korean Surgical Society
- Member, Korean Society of Coloproctology
- Member, Korean Society of Surgical Oncology
- Member, Korean Surgical Infection Society
- Member, Korean Society of Endo-Laparoscopic & Robotic Surgery
- Member, European Society of Surgical Oncology
- Member, Society of Surgical Oncology
- Member, American Association for Cancer Research
- Member, European Association of Endoscopic Surgery
- Fellow of American College of Surgeons

16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

In-Person & Virtual

Korean Society of Medical Oncology

• Main Scientific Publications:

2023

- Kim JK, Rhee YY, Bae JM, Kim JH, Koh SJ, Lee HJ, Im JP, Kim MJ, Ryoo SB, Jeong SY, Park KJ, <u>Park JW</u>, Kang GH. Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer. BMC Cancer. 2022 Aug 6;22(1):861.
- Jung SH, Hao J, Shivakumar M, Nam Y, Kim J, Kim MJ, Ryoo SB, Choe EK, Jeong SY, Park KJ, Park SC, Sohn DK, Oh JH, Won HH, Kim D, <u>Park JW</u>. Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index. Br J Cancer. 2022 Jun;126(11):1539-1547.
- <u>Park JW</u>, Kang SB, Hao J, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim JS, Lee HS, Kim JH, Jeong SY, Oh JH. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021 Apr 22:S2468-1253(21)00094-7.
- 4. Kim MJ, <u>**Park JW**</u>, Lee MA, Lim HK, Kwon YH, Ryoo SB, Park KJ, Jeong SY. Two dominant patterns of low anterior resection syndrome and their effects on patients' quality of life. Sci Rep. 2021 Feb 11;11(1):3538.
- Cho NY, <u>Park JW</u>, Wen X, Shin YJ, Kang JK, Song SH, Kim HP, Kim TY, Bae JM, Kang GH. Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers. Diagnostics (Basel). 2020 Dec 31;11(1):51.
- 6. <u>**Park JW**</u>, Chang HJ, Yeo HY, Han N, Kim BC, Kong SY, Kim J, Oh JH. The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parameters. Br J Cancer. 2020 Aug;123(4):610-618.
- Song N, Huang D, Jang D, Kim MJ, Jeong SY, Shin A, <u>Park JW</u>. Optimal Body Mass Index Cut-off Point for Predicting Colorectal Cancer Survival in an Asian Population: A National Health Information Database Analysis. Cancers (Basel). 2020 Mar 30;12(4).
- 8. Lee KY, <u>Park JW</u>, Lee KY, Cho S, Kwon YH, Kim MJ, Ryoo SB, Jeong SY, Park KJ. Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer. Sci Rep. 2019 Aug 14;9(1):11846
- Lee KY, <u>Park JW</u>, Lee KY, Cho S, Kwon YH, Kim MJ, Ryoo SB, Jeong SY, Park KJ. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study. Int J Colorectal Dis. 2019 Apr;34(4):629-639.
- 10. Lee KY, <u>**Park JW**</u>, Lee KY, Cho S, Kwon YH, Kim MJ, Ryoo SB, Jeong SY, Park KJ. Safety of temporary ileostomy via specimen extraction site in rectal cancer patients who underwent laparoscopic low anterior resection. Sci Rep. 2019 Feb 19;9(1):2316.

16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

In-Person & Virtual

Korean Society of Medical Oncology

2023

- 11. Han EC, <u>Park JW</u>, Kwon YH, Song I, Kim JS, Ryoo SB, Jeong SY, Park KJ. Do the Oncological and Surgical Outcomes of Young and Older Women Differ in the Treatment of Colorectal Cancer?. J Womens Health (Larchmt). 2019 Feb;28(2):258-267
- Lee KY, <u>Park JW</u>, Song I, Lee KY, Cho S, Kwon YH, Kim MJ, Ryoo SB, Jeong SY, Park KJ. Prognostic significance of sealed-off perforation in colon cancer: a prospective cohort study. World J Surg Oncol. 2018 Dec 4;16(1):232.
- 13. Park BK, <u>Park JW</u>, Han EC, Ryoo SB, Han SW, Kim TY, Chie EK, Jeong SY, Park KJ. Systemic inflammatory markers as prognostic factors in stage IIA colorectal cancer. J Surg Oncol. 2016 Aug;114(2):216-21.
- 14. Jeong SY, <u>Park JW</u>, Nam BH, Kim S, Kang SB, Lim SB, Choi HS, Kim DW, Chang HJ, Kim DY, Jung KH, Kim TY, Kang GH, Chie EK, Kim SY, Sohn DK, Kim DH, Kim JS, Lee HS, Kim JH, Oh JH. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jun;15(7):767-74.